Brief Report: Use and Side Effects of Sodium–Glucose Transporter 2 Inhibitors Among US People With HIV With Clinical Indications
Meghan E. Sise(Harvard University), Markella V. Zanni(Harvard University), Mabel Toribio(Boston College), Nurit Katz‐Agranov(Massachusetts General Hospital), Destiny Harden(Massachusetts General Hospital), Claudia G. Durbin(Harvard University), Ian A. Strohbehn(Massachusetts General Hospital), Tomas G. Neilan(Albert Einstein College of Medicine), Daiana Moreno(Massachusetts General Hospital)
Cited by 10
Related Papers
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589